# US 2009/0291972 A1 · Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0291972 A1
- Document ID: US20090291972A1
- Status: Published application
- Kind: A1
- Application number: 12/355,949
- Filed: 2009-01-19
- Published: 2009-11-26
- Earliest claimed: 2008-01-18
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: David J. SHAPIRO; Chengjian Mao; Milu Tresa Cherian; Nicole M. Patterson
- Web page: https://patentgrep.com/patent/US20090291972A1

## CPC

- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure herein relates to nuclear hormone receptors including steroid hormone receptors, for example in connection with estrogen, progesterone, and androgen. Embodiments of compositions and methods are disclosed including such relating to compounds, including substituted theophyllines, capable of functioning as inhibitors of estrogen receptor alpha-mediated gene expression and having the ability to modify cancer cells and treat cancer, including breast cancers and resistant breast cancers, particularly those that are resistant to tamoxifen. In embodiments, methods of inhibiting breast cancer cells and resistant breast cancer cells are provided. In embodiments, a useful inhibitor compound includes TPSF/NSC 97998 and other compounds.

## Claims

### Claim 1

A method of inhibiting growth of a cancer cell comprising contacting said cell with an effective amount of a compound having formula FX2:
wherein X or Y each independently is S, O, or Se;
R1 or R2 each independently is H or C1-6 alkyl;
R3 is —S—CH2, —O—CH2—, —CH2—S, or —CH2—O—;
R4 is —C═O, —NH—C═O, —CH2—, or null;
R5 is F, Cl, Br, I, At, H, or other group with electronegativity from 1.5 to 4.0; and
n is 1 to 6.

### Claim 2 (depends on 1)

The method of claim 1 wherein the cancer cell is a human cancer cell.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cancer cell is a breast cancer cell.

### Claim 4 (depends on 1)

The method of claim 1 wherein the cancer cell is a resistant cancer cell.

### Claim 5 (depends on 4)

The method of claim 4 wherein said resistant cancer cell has resistance to a chemotherapeutic agent selected from the group consisting of tamoxifen, 4-hydroxytamoxifen (OHT); a selective estrogen receptor modulator, and an aromatase inhibitor.

### Claim 6 (depends on 1)

The method of claim 1 wherein the compound has a structural formula selected from the group consisting of compounds having formulas corresponding to TPSF/97998, 99676, and TPBM/95910:

### Claim 7 (depends on 1)

The method of claim 1 wherein the compound has a structural formula of compound TPSF/97998,

### Claim 8

A method of inhibiting growth of a cancer cell comprising contacting said cell with an effective amount of a compound having formula FX1:
wherein X and Y independently can be oxygen or sulfur; R can be A, B, C, or D; wherein A is alkyl; B is thioalkyl; C is arylalkyl, and D is cycloalkyl; and wherein each component A, B, C, or D independently is optionally substituted.

### Claim 9 (depends on 8)

The method of claim 8 wherein the compound is selected from the group consisting of compounds having formulas corresponding to TPSF/97998, 99676, TPEP/74361, and TPBM/95910:

### Claim 10

A method of treating cancer comprising administering to a patient in need thereof an effective amount of a compound having formula FX2 or a pharmaceutical formulation thereof:
wherein X or Y each independently is S, O, or Se;
R1 or R2 each independently is H or C1-6 alkyl;
R3 is —S—CH2, —O—CH2—, —CH2—S, or —CH2—O—;
R4 is —C═O, —NH—C═O, —CH2—, or null;
R5 is F, Cl, Br, I, At, H, or other group with electronegativity from 1.5 to 4.0; and
n is 1 to 6.

### Claim 11 (depends on 10)

The method of claim 10 wherein said cancer is human breast cancer.

### Claim 12 (depends on 10)

The method of claim 10 wherein said cancer is a resistant cancer.

### Claim 13 (depends on 12)

The method of claim 12 wherein said resistant cancer has resistance to a chemotherapeutic agent selected from the group consisting of tamoxifen, 4-hydroxytamoxifen (OHT); a selective estrogen receptor modulator, and an aromatase inhibitor.

### Claim 14 (depends on 10)

The method of claim 10 wherein said cancer is a resistant breast cancer.

### Claim 15 (depends on 10)

The method of claim 10 wherein the compound has a structural formula selected from the group consisting of compounds having formulas corresponding to TPSF/97998, 99676, and TPBM/95910:

### Claim 16 (depends on 10)

The method of claim 10 wherein the compound has a structural formula of compound TPSF/97998,

### Claim 17

A method of treating cancer comprising administering to a patient in need thereof an effective amount of a compound having formula FX1 or a pharmaceutical formulation thereof:
wherein X and Y independently can be oxygen or sulfur; R can be A, B, C, or D; wherein A is alkyl; B is thioalkyl; C is arylalkyl, and D is cycloalkyl; and wherein each component A, B, C, or D independently is optionally substituted.

### Claim 18 (depends on 17)

The method of claim 17 wherein said cancer is human breast cancer.

### Claim 19 (depends on 17)

The method of claim 17 wherein said cancer is a resistant cancer.

### Claim 20 (depends on 17)

The method of claim 17 wherein the compound is selected from the group consisting of compounds having formulas corresponding to TPSF/97998, 99676, TPEP/74361, and TPBM/95910:

### Claim 21 (depends on 17)

The method of claim 17 wherein the compound has a structural formula of compound TPSF/97998,
